The cost-benefit of long-acting injectable buprenorphine as a treatment for opioid use disorder
Edge Health was commissioned by Camurus to evaluate the potential benefits of sustained engagement in treatment with long-acting injectable buprenorphine, alongside its associated costs, in order to assess its overall socioeconomic impact in England as a treatment for opioid use disorder.